What should you pay attention to when using adalimumab?

Adalimumab (Adalimumab) is used to treat rheumatoid arthritis (RA), psoriasis, active psoriatic arthritis(PA), When treating atopic dermatitis (AD), ulcerative colitis, Crohn's disease (CD) , and ankylosing spondylitis, special attention needs to be paid to the following matters to ensure patient safety and effectiveness of treatment.

First, the risk of serious infection is one of the most important considerations when using adalimumab. Adalimumab is an immunosuppressant that may make patients less resistant to infection. Therefore, patients should be carefully evaluated for active infection before initiating treatment and monitored for signs and symptoms of infection during treatment. If the patient develops a serious infection, the drug should be discontinued immediately and appropriate anti-infective treatment should be initiated.

Secondly, the risk of malignant tumors also needs attention. Research suggests that long-term use of adalimumab may be associated with the development of certain cancers, particularly lymphoma and skin cancer. Therefore, physicians should carefully evaluate the need for adalimumab in patients with a history of cancer or high-risk factors and conduct regular cancer screenings.

In addition, allergic reactions are also a problem that requires vigilance. Some patients may experience allergic reactions, including rash, itching, difficulty breathing, etc. when taking adalimumab. If patients develop these symptoms, they should stop taking the medication immediately and seek medical help.

Hepatitis B virus reactivation is one of the important risks when using adalimumab. For patients previously infected with hepatitis B, the hepatitis B virus carrier status needs to be assessed before treatment, and liver function and viral load should be closely monitored during treatment to prevent reactivation of the virus.

Neural responses are also an area of concern. Adalimumab may be associated with central nervous system side effects, such as neuropathy or multiple sclerosis. Therefore, if patients experience headache, blurred vision, or other neurological symptoms, they should be promptly evaluated and decided whether to continue taking the medication.

Blood reactions are another concern. The use of adalimumab may cause adverse reactions in the blood system, such as leukopenia, thrombocytopenia, etc. Therefore, routine blood tests should be monitored regularly throughout the entire treatment process to detect abnormalities in a timely manner.

Particular caution is required when using adalimumab in patients with heart failure. Because this drug may aggravate the symptoms of heart failure, patients with heart failure should be used under strict monitoring to avoid exacerbation of the condition.

Finally, caution is advised when using adalimumab in patients with autoimmune diseases. Adalimumab may induce or aggravate autoimmune diseases. Therefore, patients should be followed up regularly during treatment to pay attention to the occurrence of autoimmune reactions.

In summary, the use of adalimumab requires a comprehensive assessment of the patient's health status and regular monitoring during treatment to ensure safety and efficacy. Medical staff should fully communicate with patients, inform them of possible risks and precautions, and actively manage potential adverse reactions.

Reference materials:https://www.drugs.com/adalimumab.html